Establishment of a Robust mAb Subunit Product Quality Attribute Monitoring Method Suitable for Development, Process Monitoring, and QC Release

Importance of the Topic

The robust monitoring of monoclonal antibody subunit quality attributes is critical in biopharmaceutical development, enabling faster process adjustments, reliable QC release, and comprehensive product characterization.

Study Objectives and Overview

This study establishes a subunit-based multi-attribute monitoring method on TOF-based LC-MS platforms (BioAccord and Vion), aiming to complement peptide MAM by improving throughput and simplifying data analysis while tracking glycosylation, glycation, oxidation, and sequence variants.

Methodology and Instrumentation

Sample Preparation:

• 50 μg antibody digested with IdeS enzyme at 37 °C for 1 h
• Partial reduction with 5 mM DTT for 30 min at 37 °C
• Optional PNGaseF treatment for deglycosylation

Chromatography and Mass Spectrometry:

• UPLC I-Class system with ACQUITY BEH C4 column (2.1 × 50 mm, 1.7 μm) at 80 °C
• Gradient elution with 0.1% formic acid in water and acetonitrile, 15 min run
• BioAccord and Vion IMS QTof detectors
• Data processing using UNIFI/waters_connect with intact protein workflow

Key Results and Discussion

Robustness:

• Glycation RSD <8% for LC and Fd over 18 injections
• Fc glycosylation species >0.5% abundance showed <5% RSD

Case Studies:

• Cetuximab glycoprofiling localized distinct Fd and Fc glycan profiles with <3% RSD
• Sequence variant quantitation of spiked trastuzumab was linear (R²=0.9994) from 1–50%
• Forced oxidation of NIST mAb revealed Fc subunit oxidation shifts quantifiable under H₂O₂ stress

Limitations:
An inability to resolve isobaric modifications (e.g., deamidation) and only subunit-level localization requires peptide mapping for site-specific analysis

Advantages and Practical Applications

• Simplified sample preparation with fewer artifacts
• Shorter analysis times and higher throughput
• Rich attribute coverage including glycoforms, oxidation, and variants
• Compliance-ready automated data analysis

Future Trends and Applications

Integration of subunit MAM into automated bioprocessing workflows, expansion to emerging biotherapeutic modalities, coupling with high-resolution instrumentation, and hybrid strategies combining subunit and peptide mapping for comprehensive attribute characterization

Conclusion

Subunit-based MAM on TOF platforms offers a reproducible, rapid, and high-throughput solution for mAb quality attribute monitoring, supporting development, manufacturing, and QC release functions

References

1. Dong J et al. High-Throughput, Automated Protein A Purification Platform with Multiattribute LC-MS Analysis for Advanced Cell Culture Process Monitoring. Anal Chem. 2016;88:8673–8679.
2. Sokolowska I et al. Subunit mass analysis for monitoring antibody oxidation. mAbs. 2017;9(3):498–505.
3. Sokolowska I et al. Implementation of a High-Resolution LC-MS Method in QC Laboratories for Release and Stability Testing of a Commercial Antibody. Anal Chem. 2020;92:2369–2373.
4. Glycoworks RapiFluor MS N-glycan kit. Manual. Waters; 2019.
5. Shion H et al. Enabling Routine and Reproducible Intact Mass Analysis When Data Integrity Matters. Waters App Note. 2019.
6. Giddens J et al. Site-selective Chemoenzymatic Glycoengineering of Fab and Fc Glycans of a Therapeutic Antibody. PNAS. 2018;115(47):12023–12027.
7. Ayoub D et al. Correct Primary Structure Assessment and Extensive Glyco-Profiling of Cetuximab by Combined Mass Spectrometry Techniques. mAbs. 2013;5(5):699–710.
8. Lin T et al. Evolution of a Comprehensive, Orthogonal Approach to Sequence Variant Analysis for Biotherapeutics. mAbs. 2019;11(1):1–12.